Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection

Article metrics

Abstract

Severe acute respiratory syndrome (SARS) is caused by infection of a previously undescribed coronavirus (CoV). L-SIGN, encoded by CLEC4M (also known as CD209L), is a SARS-CoV binding receptor that has polymorphism in its extracellular neck region encoded by the tandem repeat domain in exon 4. Our genetic risk association study shows that individuals homozygous for CLEC4M tandem repeats are less susceptible to SARS infection. L-SIGN is expressed in both non-SARS and SARS-CoV–infected lung. Compared with cells heterozygous for L-SIGN, cells homozygous for L-SIGN show higher binding capacity for SARS-CoV, higher proteasome-dependent viral degradation and a lower capacity for trans infection. Thus, homozygosity for L-SIGN plays a protective role during SARS infection.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: L-SIGN is expressed in non-SARS lung and also in the lung and small bowel of patients fatally infected with SARS.
Figure 2: L-SIGN is a binding receptor for SARS-CoV and mediates proteasome-dependent viral degradation.
Figure 3: L-SIGN facilitates trans, but not cis, infection of SARS-CoV.
Figure 4: L-SIGN expressed on permissive Vero E6 cells captured/adsorbed infectious viruses released into the supernatant.
Figure 5: Homozygous, but not heterozygous, L-SIGN reduced the final total viral genomic and subgenomic copy number in a closed infection system.

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. 1

    Peiris, J.S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325 (2003).

  2. 2

    Ksiazek, T.G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953–1966 (2003).

  3. 3

    Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967–1976 (2003).

  4. 4

    Bonavia, A., Zelus, B.D., Wentworth, D.E., Talbot, P.J. & Holmes, K.V. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J. Virol. 77, 2530–2538 (2003).

  5. 5

    Breslin, J.J. et al. Human coronavirus 229E: receptor binding domain and neutralization by soluble receptor at 37 degrees C. J. Virol. 77, 4435–4438 (2003).

  6. 6

    Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454 (2003).

  7. 7

    Kliger, Y. & Levanon, E.Y. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy. BMC Microbiol. 3, 20 (2003).

  8. 8

    Soilleux, E.J., Barten, R. & Trowsdale, J. DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J. Immunol. 165, 2937–2942 (2000).

  9. 9

    Soilleux, E.J. DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) and DC-SIGN-related (DC-SIGNR): friend or foe? Clin. Sci. (Lond.) 104, 437–446 (2003).

  10. 10

    Bashirova, A.A. et al. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J. Exp. Med. 193, 671–678 (2001).

  11. 11

    Mitchell, D.A., Fadden, A.J. & Drickamer, K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J. Biol. Chem. 276, 28939–28945 (2001).

  12. 12

    Feinberg, H., Mitchell, D.A., Drickamer, K. & Weis, W.I. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294, 2163–2166 (2001).

  13. 13

    Guo, Y. et al. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat. Struct. Mol. Biol. 11, 591–598 (2004).

  14. 14

    Pohlmann, S. et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc. Natl. Acad. Sci. USA 98, 2670–2675 (2001).

  15. 15

    Pohlmann, S. et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77, 4070–4080 (2003).

  16. 16

    Lin, G. et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77, 1337–1346 (2003).

  17. 17

    Koppel, E.A. et al. Identification of the mycobacterial carbohydrate structure that binds the C-type lectins DC-SIGN, L-SIGN and SIGNR1. Immunobiology 209, 117–127 (2004).

  18. 18

    Yang, Z.Y. et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78, 5642–5650 (2004).

  19. 19

    Marzi, A. et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 78, 12090–12095 (2004).

  20. 20

    Jeffers, S.A. et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 101, 15748–15753 (2004).

  21. 21

    Lin, M. et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med. Genet. 4, 9 (2003).

  22. 22

    Ng, M.H. et al. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J. Infect. Dis. 190, 515–518 (2004).

  23. 23

    Chan-Yeung, M. Severe acute respiratory syndrome (SARS) and healthcare workers. Int. J. Occup. Environ. Health 10, 421–427 (2004).

  24. 24

    Poon, L.L. et al. Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS). Clin. Chem. 49, 953–955 (2003).

  25. 25

    Rota, P.A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399 (2003).

  26. 26

    Marra, M.A. et al. The Genome sequence of the SARS-associated coronavirus. Science 300, 1399–1404 (2003).

  27. 27

    Nardone, L.L. & Andrews, S.B. Cell line A549 as a model of the type II pneumocyte. Phospholipid biosynthesis from native and organometallic precursors. Biochim. Biophys. Acta 573, 276–295 (1979).

  28. 28

    Snijder, E.J. et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331, 991–1004 (2003).

  29. 29

    Drosten, C. et al. Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus. J. Clin. Microbiol. 42, 2043–2047 (2004).

  30. 30

    Lichterfeld, M. et al. The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the susceptibility to HIV infection and the progression to AIDS. Clin. Immunol. 107, 55–59 (2003).

  31. 31

    Lee, N. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986–1994 (2003).

  32. 32

    Tsang, K.W. et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1977–1985 (2003).

  33. 33

    To, K.F. et al. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. J. Pathol. 202, 157–163 (2004).

  34. 34

    Soilleux, E.J. et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J. Leukoc. Biol. 71, 445–457 (2002).

  35. 35

    Guan, M. et al. Evaluation and validation of an enzyme-linked immunosorbent assay and an immunochromatographic test for serological diagnosis of severe acute respiratory syndrome. Clin. Diagn. Lab. Immunol. 11, 699–703 (2004).

  36. 36

    Xiong, H. et al. A novel gene encoding a TIG multiple domain protein is a positional candidate for autosomal recessive polycystic kidney disease. Genomics 80, 96–104 (2002).

  37. 37

    Erler, J.T. et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell. Biol. 24, 2875–2889 (2004).

Download references

Acknowledgements

We are indebted to L.-C. Tsui and P. Sham for their advice and support. We thank K.F. To and P. Beh for providing autopsy materials of patients fatally infected with SARS. We thank L.Y.C. Yam, S.T. Lai, C.M. Chu, T.Y. Wong, E. Chow, E.S.K. Ma, E.Y.T. Chan, R.Y.L. Chen and M.M. Garcia-Barcelo for sample collection and C. Wong, J. Chan, W. Liu and W.C. Xue for their technical support. This project was funded by the SARS Research Fund from the University of Hong Kong, the European Research Project SARS-DTV, the US National Institute of Allergy and Infectious Diseases, the Research Fund for the Control of Infectious Diseases of Hong Kong and the Research Grant Council, HKSAR, China.

Author information

Correspondence to Ui-Soon Khoo or Chen-Lung S Lin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Fig. 1

Reduction of the total SARS-CoV ORF-1b copy numbers is not due to viral dissociation from L-SIGN. (PDF 90 kb)

Supplementary Fig. 2

A549 cells do not express ACE2 and L-SIGN, and SARS-CoV binding to L-SIGN-transfected A549 cells also underwent degradation over time. (PDF 179 kb)

Supplementary Fig. 3

L-SIGN delivered SARS-CoV to Vero E6 cells in trans, but no difference was noted among N7, N7/N5 and N5 L-SIGN transfectants after 48 h incubation. (PDF 101 kb)

Supplementary Fig. 4

L-SIGN expressed in ACE2-transfected CHO cells or in ACE2-trasnfected A549 cells did not facilitate cis infection of SARS-CoV. (PDF 153 kb)

Supplementary Fig. 5

48 h supernatant from SARS-CoV infected N7 L-SIGN/Vero E6 cells contained a lower number of infectious virions than that from the infected N7/N5 L-SIGN/Vero E6 cultures. (PDF 98 kb)

Supplementary Fig. 6

Co-cultures of stable clones of homozygous L-SIGN/CHO cells with Vero E6 cells in a closed infection system resulted in a reduced final SARS-CoV titer. (PDF 231 kb)

Supplementary Fig. 7

CD68bright cells did not express SARS-CoV mRNA in fatal SARS lung. (PDF 138 kb)

Supplementary Table 1

Genotype and allele frequencies of CLEC4M (L-SIGN) in Chinese random controls and Caucasians of European descent (CEPH). (PDF 90 kb)

Supplementary Table 2

List of primers used. (PDF 72 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading